Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID .

OMF Adds a Fourth ME / CFS Collaborative Research Center

BREAKING NEWS

We are pleased to announce that we have added a fourth ME / CFS Collaborative Research Center (CRC) to join our End ME / CFS Project.

Directed by Alain Moreau, PhD, the ME / CFS Collaborative Research Center at CHU Sainte-Justine/Université de Montréal in Québec, Canada will serve to increase our international collaborative efforts.

Dr. Moreau and his lab have been researching Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) for several years. After meeting Ronald W. Davis, PhD, OMF Scientific Advisory Board Director, and OMF CEO Linda Tannenbaum in 2017, Dr. Moreau has been a part of the ME / CFS working group and has presented multiple times at the community symposium held at Stanford University. Additionally, he organized the first ME / CFS Canadian Collaborative Conference held in Montreal in May 2018.

“I initially decided to invite Dr. Moreau to join our ME / CFS Working Group because he demonstrated that he could take multiple novel approaches to understand the disease. His work will be very complementary to the research of other investigators. The CRC in Montreal extends our international collaboration for solving ME / CFS.” Ronald W. Davis, PhD

About the Research

The new ME / CFS Collaborative Research Center at the Université de Montréal is searching for the cause of the disease with a focus on actionable therapeutic targets. Their innovative research program is at the frontier of genetic predisposition and external factors that may have altered the gene expression in ME / CFS patients (epigenetic changes).

They hope that monitoring different biomarker changes during a stress test will shed light on the pathophysiology of ME / CFS and help to identify specific molecular signatures. In parallel, they intend to develop better clinical tools allowing clinicians to diagnose ME / CFS and select the best treatments to address their medical needs. Ultimately, they hope to find a cure to end ME / CFS.

 

Dr. Moreau’s Research Team at the ME / CFS Collaborative Research Center CHU Sainte-Justine/Université de Montréal in Québec, Canada

Learn more about the ME / CFS Collaborative Research Center, Université de Montréal

About Dr. Moreau

Alain Moreau, PhD, is a Full Professor in the Department of Stomatology, Faculty of Dentistry and Department of Biochemistry and Molecular Medicine, Faculty of Medicine, at Université de Montréal, Montréal, Québec, Canada. Additionally, Dr. Moreau is the Director of Network for Canadian Oral Health Research. He is the Scientific Director of the Viscogliosi Laboratory in Molecular Genetics of Musculoskeletal Diseases, Sainte-Justine University Research Center, Montréal, Québec.

Dr. Moreau’s chief interests of study are pediatric scoliosis, osteoarthritis, osteoporosis, and Myalgic Encephalomyelitis. Dr. Moreau is a member of the Open Medicine Foundation Scientific Advisory Board and is the Director of the Interdisciplinary Canadian Collaborative Myalgic Encephalomyelitis Research Network, a national research network funded by the Canadian Institute of Health Research.

______________________________________________________________

We are so proud of the great minds from across the globe that have joined The End ME / CFS Project. Dr. Moreau’s colleagues are from Canada, France, Iran, Moldova, China, Egypt, Columbia, Spain, Russia, and Romania!

WON’T YOU SUPPORT THE WORK OF OUR
INTERNATIONAL TEAM OF RESEARCHERS?

Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo